US FDA: Carcinogenic Potency Categorization Approach for Nitrosamine Impurities

Recommendation
Wednesday, 19 November 2025 9 .00 - 16.30 h
In January 2025, the US FDA has published in its newsroom on the CDER website the article called "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach". It is structured in the following chapters and passages:
- Background
- Materials and Methods
- Results
A) α-Hydrogen features in the format "n,n" where the lowest number of hydrogens is listed first
B) Deactivating features
C) Activating features - Discussion
- Other resources
The article clearly explains the historical background of developing and establishing the "Carcinogenic Potency Categorization Approach (CPCA)" and provides an overview of deactivating and activating features in a listed order.
The complete article "Determining Recommended Acceptable Intake Limits for N-nitrosamine Impurities in Pharmaceuticals: Development and Application of the Carcinogenic Potency Categorization Approach" can be checked in the newsroom of CDER's website.
Related GMP News
12.11.2025EMA/CMDh: Nitrosamines Q&A Document updated again
12.11.2025EDQM: New CEP Document published
22.10.2025FDA Warning Letter: Missing Stability Testings
15.10.2025Data Integrity and the ICH Q7 Guidance - Part II
08.10.2025US FDA Warning Letter: Inadequate Investigation of Complaints
